Applied Filters
Vectura wins additional $10m patent damages against GSK
A district court has upped Vectura’s award of $89.7 million in damages by $10m, after a jury trial earlier this year found that GlaxoSmithKline has willfully infringed one of its patents.
Pharma industry challenges Canada’s drug pricing plan
Innovative Medicines Canada, an association that represents drugmakers in Canada, has challenged the overhaul of Canada’s drug-pricing regime.
Federal Circuit blocks Sandoz generic
The US Court of Appeals for the Federal Circuit has ruled that claims in an Allergan patent detailing the results of a glaucoma treatment are material to its patentability, after an unsuccessful invalidation appeal brought by Sandoz.
Delhi court approves Natco generic of Novartis cancer drug
The Delhi High Court has cleared the way for a generic version of Novartis’ small-cell lung cancer drug Ceritinib, after the Swiss pharmaceutical company’s patent was revoked.
PTAB institutes IPR of Nalox-1 opioid overdose treatment
The US Patent Trial and Appeal Board has instituted an inter partes review into a patent covering an opioid overdose treatment owned by Nalox-1 Pharmaceuticals.
Takeda subsidiary ordered to pay Bayer $182m after overturn bid fails
A Takeda subsidiary cannot overturn a $155 million jury verdict that it infringed one of Bayer’s patents, a district court has ruled.
Gilead challenges US govt patents on HIV drug Truvada
Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.
Novo Nordisk seeks to block Mylan generic
Danish pharmaceutical company Novo Nordisk has sued Mylan in a US court over a proposed generic of diabetes drug Victoza (liraglutide).
Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug
Amneal and three other generic makers have agreed to pay $1.54 million to settle a class-action lawsuit, which alleged the companies engaged in an unlawful scheme to maintain their monopoly over an Alzheimer’s drug.
Fed Circuit majority ‘problematically’ adds new rule in Actavis suit: chief judge
The US Court of Appeals for the Federal Circuit yesterday, August 15, blocked Actavis’s attempt to market a generic version of Nalpropion Pharmaceuticals’ weight-loss drug Contrave.
